Day: October 26, 2021

EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) — Zymergen Inc. (Nasdaq: ZY) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, 2021. The company’s management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biofacturing company using biology to reimagine the world. Zymergen partners with nature to design, develop and manufacture bio-based breakthrough products that deliver value to customers in a broad range of industries. A unique combination of biology, chemistry, software and automation enables the company to design and create new materials. Investor...

WARSAW, Ind., Oct. 26, 2021 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Mark Throdahl, Executive Chairman, are scheduled to participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021.Event: Stifel 2021 Virtual Healthcare Conference   Format: Fireside Chat and One-on-One Meeting   Date: Monday, November 15, 2021   Location: Webcast   Time: 10:00am ETAn audio webcast of the presentation will be available online at the OrthoPediatrics’ investor relations website, http://ir.orthopediatrics.com....

NEW YORK, Oct. 26, 2021 (GLOBE NEWSWIRE) — Reservoir Media, Inc. (NASDAQ: RSVR) (“Reservoir” or the “Company”), an award-winning independent music company, today announced that it will release financial results for the second fiscal quarter ended September 30, 2021 before market open on Tuesday, November 9, 2021. Reservoir will host a conference call to discuss its results at 10 a.m. Eastern Standard Time the same day. A live audio webcast of Reservoir’s second fiscal quarter results discussion will be accessible under the Events and Presentations section of the Company’s Investor Relations website at https://investors.reservoir-media.com/news-and-events/events-and-presentations. To participate in the conference call, please dial 1-844-249-2008 (U.S. and Canada) and 224-619-3936 (International) and enter the Conference ID 7745548....

AUSTIN, Texas, Oct. 26, 2021 (GLOBE NEWSWIRE) — Ideal Power Inc. (Nasdaq: IPWR), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bi-directional power switches, today announced that management will hold a conference call on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended September 30, 2021. A press release detailing these results will be issued prior to the call. Ideal Power President and CEO Dan Brdar and CFO Tim Burns will host the conference call, followed by a question-and-answer period. To access the call, please use the following information:Date:   Wednesday, November 10, 2021Time:   4:30 p.m. EDT, 1:30 p.m. PDTToll-free dial-in number:   1-866-248-8441International dial-in number:   1-323-289-6581Conference...

SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced it will report financial results for the third quarter 2021 on Tuesday, November 9, 2021, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast DetailsThe conference call can be accessed by dialing +1 (877) 407-3982 for U.S. participants or +1 (201) 493-6780 for international participants and referencing conference ID #13723538. Interested parties may access a live and archived webcast of the event on the “Investor Relations” section of the Company’s website at: https://ir.augmedix.com/. About Augmedix Augmedix, Inc. (Nasdaq: AUGX) is a leading digital...

FREMONT, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8th, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com About Cytek BiosciencesCytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology....

WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced the closing of its previously announced initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share. The aggregate gross proceeds to Xilio from the offering were approximately $117.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Xilio. In addition, Xilio has granted the underwriters a 30-day option to purchase up to an additional 1,102,950 shares of its common stock at the initial public offering price less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Select Market on October 22, 2021...

PORTSMOUTH, N.H., Oct. 26, 2021 (GLOBE NEWSWIRE) — Bottomline (NASDAQ:EPAY), a leading provider of financial technology that makes business payments simple, smart and secure, today announced that the Company will release its first quarter fiscal year 2022 financial results on Tuesday, November 9, 2021 after the market close. Following the release, management will host a conference call and webcast to discuss the Company’s results.What: Bottomline First Quarter Fiscal Year 2022 Financial Results Conference CallWhen: Tuesday, November 9, 2021Time: 5:00 p.m. ETLive Call: US: (877) 407-3980  International: (201) 689-8475Webcast: https://investors.bottomline.comA replay of the conference call will be available from 8:00 p.m. on November 9, 2021 through midnight on November 15, 2021. The replay can be accessed by...

NOVATO, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, November 2, 2021 at 5pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2021. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call by phone, dial (855) 797-6910 (USA) or (262) 912-6260 (International) and enter the passcode 1098326. The replay of the call will be available for one year. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel...

Angion to host a conference call at 4:30 p.m. EDT UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF). ANG-3777 showed a modest but not statistically significant difference in eGFR of 53.3mL/min/1.73m2 versus 50.4mL/min/1.73m2 for placebo (2.9 mL/min/1.73m2, p=0.33). In addition, ANG-3777 demonstrated an inconsistent benefit on key secondary endpoints. Based upon these data, it is not expected there is sufficient evidence to support an indication in the studied...